Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TBPH 
Theravance Biopharma Inc (TBPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: TBPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.26% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 704.55M USD | Price to earnings Ratio 58.29 | 1Y Target Price 20 |
Price to earnings Ratio 58.29 | 1Y Target Price 20 | ||
Volume (30-day avg) 4 | Beta -0.03 | 52 Weeks Range 7.90 - 15.15 | Updated Date 10/12/2025 |
52 Weeks Range 7.90 - 15.15 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.88% | Operating Margin (TTM) -10.4% |
Management Effectiveness
Return on Assets (TTM) -5.65% | Return on Equity (TTM) 6.23% |
Valuation
Trailing PE 58.29 | Forward PE 9.43 | Enterprise Value 416236434 | Price to Sales(TTM) 9.13 |
Enterprise Value 416236434 | Price to Sales(TTM) 9.13 | ||
Enterprise Value to Revenue 5.39 | Enterprise Value to EBITDA 9.03 | Shares Outstanding 50361296 | Shares Floating 21894573 |
Shares Outstanding 50361296 | Shares Floating 21894573 | ||
Percent Insiders 4.37 | Percent Institutions 92.94 |
Upturn AI SWOT
Theravance Biopharma Inc
Company Overview
History and Background
Theravance Biopharma Inc. was formed in 2014 as a spin-off from Theravance, Inc. It focuses on the discovery, development, and commercialization of medicines primarily for respiratory and gastrointestinal diseases. Theravance has evolved through strategic partnerships and acquisitions to build its portfolio.
Core Business Areas
- Respiratory Diseases: Development and commercialization of inhaled therapies for respiratory diseases, including COPD and asthma.
- Gastrointestinal Diseases: Development of therapies for gastrointestinal (GI) diseases, such as Crohn's disease.
- Research and Development: Discovery of new therapeutic candidates through internal research and development programs.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure includes departments for research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Yupelri (revefenacin): A once-daily nebulized bronchodilator for the maintenance treatment of COPD. Competitors include other long-acting muscarinic antagonists (LAMAs) such as Spiriva (tiotropium) from Boehringer Ingelheim and Incruse Ellipta (umeclidinium) from GSK. Market share data is fluctuating and difficult to pinpoint precisely without up-to-date reports, but Yupelri has been working to expand its presence in the nebulized LAMA space.
- Vibegron: Vibegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. The competition includes Mirabegron, and several anti-muscarinic drugs
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. Demand for respiratory and GI therapies is driven by the prevalence of chronic diseases and an aging population.
Positioning
Theravance Biopharma is positioned as a specialty pharmaceutical company focusing on innovative therapies for respiratory and GI diseases. Its competitive advantages include its expertise in drug discovery, development, and commercialization, as well as its partnerships with larger pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for COPD and GI therapies is substantial, estimated to be in the billions of dollars globally. Theravance Biopharma is positioned to capture a portion of this market through its existing products and pipeline candidates.
Upturn SWOT Analysis
Strengths
- Focus on respiratory and GI diseases
- Expertise in drug discovery and development
- Strategic partnerships
- Established commercial infrastructure
- Innovative Pipeline
Weaknesses
- Reliance on a limited number of products
- Competition from larger pharmaceutical companies
- High R&D expenses
- Potential regulatory hurdles
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or products
- Geographic expansion
- Development of new drug delivery systems
- Further partnerships
Threats
- Patent expirations
- Generic competition
- Changes in healthcare regulations
- Adverse clinical trial results
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- GSK (GSK)
- AZN (AstraZeneca)
- BIIB (Biogen)
Competitive Landscape
Theravance Biopharma faces competition from larger, more established pharmaceutical companies. Its competitive advantages include its focus on specific therapeutic areas and its innovative pipeline. However, it may lack the resources and scale of its larger competitors.
Major Acquisitions
Vectura
- Year: 2022
- Acquisition Price (USD millions): 1100
- Strategic Rationale: This acquisition was intended to bolster Theravance's capabilities in inhaled drug delivery technologies and expand its pipeline of respiratory therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be analyzed based on past revenue and earnings growth rates. This information would require accessing their historical data from financial statements.
Future Projections: Future growth projections are based on analyst estimates, new product launches, and market trends. Analyst consensus estimates can be found on financial websites.
Recent Initiatives: Recent initiatives include product launches, clinical trial updates, and strategic partnerships. These activities are typically announced in press releases and investor presentations.
Summary
Theravance Biopharma focuses on respiratory and GI diseases with key products like Yupelri and Vibegron. While it has strengths in drug development and partnerships, it faces competition from larger companies. Recent acquisitions like Vectura aim to enhance its capabilities, but its success depends on navigating regulatory hurdles and market competition. The market share is also very low.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on available estimates and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theravance Biopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-05-16 | CEO & Director Mr. Rick E. Winningham M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | Website https://www.theravance.com |
Full time employees 97 | Website https://www.theravance.com | ||
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.